Rocket Pharmaceuticals Inc (RCKT) is trading up at $2.31 (+5.00%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on RCKT
One firm's current price target on Rocket Pharmaceuticals Inc: $4 — 73% above the current $2.31. Each is tracked to its date and scored the same way a member's call is.
- Goldman Sachs $2.6 → $4 by Oct 2027 Oct 8, 2026 via Investing.com · Goldman Sachs's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Rocket Pharmaceuticals Inc revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$7.57M | −$19.8M | −$71.2M | −$76.2M | −$134.3M | −$167.2M | −$224.3M | −$259.7M | −$273.2M | −$231.7M |
| Net income | −$7.57M | −$19.6M | −$74.5M | −$77.3M | −$139.7M | −$169.1M | −$221.9M | −$245.6M | −$258.7M | −$223.1M |
| EPS (diluted) | −$1.11 | −$2.88 | −$1.89 | −$1.58 | −$2.52 | −$2.67 | −$3.26 | −$2.92 | −$2.73 | −$2.01 |
| Balance sheet | ||||||||||
| Cash and equivalents | $29.8M | $18.1M | $111.4M | $185.4M | $297.1M | $232.7M | $140.5M | $55.9M | $163.6M | $77.6M |
| Total assets | $129.6M | $20.1M | $251.3M | $372.1M | $590.8M | $497.0M | $551.8M | $566.3M | $527.7M | $330.4M |
| Total liabilities | $56.5M | $4.63M | $57.3M | $64.8M | $87.3M | $42.3M | $62.1M | $73.8M | $64.5M | $53.2M |
| Shareholders' equity | $8.37M | $15.5M | $194.0M | $307.3M | $503.5M | $454.7M | $489.7M | $492.6M | $463.2M | $277.2M |
| Cash flow | ||||||||||
| Operating cash flow | −$5.50M | −$16.0M | −$53.8M | −$64.7M | −$74.6M | −$121.2M | −$178.1M | −$194.9M | −$209.7M | −$190.0M |
| Capital expenditure | $335.0K | $760.0K | $1.45M | $23.3M | $20.6M | $7.62M | $8.36M | $16.4M | $5.86M | $440.0K |
| Free cash flow | −$5.84M | −$16.7M | −$55.2M | −$87.9M | −$95.2M | −$128.8M | −$186.5M | −$211.4M | −$215.6M | −$190.5M |
| Share buybacks | $0 | $0 | $0 | $0 | $72.0K | $0 | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $0 | $0 | — | $0 | $0 |
| Operating income | −$69.4M | — | −$64.4M | −$71.1M | −$52.2M | — | −$48.5M | −$46.9M |
| Net income | −$66.7M | — | −$61.3M | −$68.9M | −$50.3M | — | −$47.6M | $123.2M |
| EPS (diluted) | −$0.71 | — | −$0.56 | −$0.62 | −$0.45 | — | −$0.42 | $1.08 |
| Balance sheet | ||||||||
| Cash and equivalents | $65.6M | $163.6M | $49.8M | $32.8M | $75.9M | $77.6M | $49.6M | $224.5M |
| Total assets | $393.7M | $527.7M | $471.1M | $421.0M | $368.0M | $330.4M | $285.4M | $423.1M |
| Total liabilities | $63.9M | $64.5M | $58.9M | $66.8M | $54.4M | $53.2M | $47.4M | $54.3M |
| Shareholders' equity | $329.8M | $463.2M | $412.1M | $354.2M | $313.7M | $277.2M | $238.0M | $368.8M |
| Cash flow | ||||||||
| Operating cash flow | −$52.1M | — | −$55.8M | −$49.0M | −$50.4M | — | −$45.4M | −$39.6M |
| Capital expenditure | $1.59M | — | $364.0K | $50.0K | −$54.0K | — | $93.0K | $8.00K |
| Free cash flow | −$53.7M | — | −$56.2M | −$49.0M | −$50.4M | — | −$45.5M | −$39.6M |
From Rocket Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
About Rocket Pharmaceuticals Inc
- Headquarters
- New York, New York From SEC filings, Oct 2026
Recent News (2)
-
Goldman Sachs upgrades Rocket Pharmaceuticals stock rating on Danon disease drug progress
Goldman Sachs upgrades Rocket Pharmaceuticals stock rating on Danon disease drug progress
-
Cantor Fitzgerald reiterates Rocket Pharmaceuticals stock rating
Cantor Fitzgerald reiterates Rocket Pharmaceuticals stock rating
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International